Journal of Antivirals & Antiretrovirals
Open Access

Significance of Immunological Responses of Interferons

Dominique Salmon^{* *}Correspondence: Dominique Salmon, Department of Immunology, Claude Bernard University, Villeurbanne, France, Email:

Author info »

Description

A class of secreted -helical cytokines known as Interferons (IFNs) is triggered in response to certain extracellular macromolecules by activating Toll-Like Receptors (TLRs). IFNs promote intra-and intercellular networks for controlling innate and acquired immunity, resistance to viral infections, and normal and tumour cell survival and death. They act in paracrine or autocrine mechanisms. IFNs use signalling molecules that were initially discovered via investigations of IFNs to trigger genes through high-affinity cell surface receptors. Changes in these pathways can also render cells resistant to a certain ligand, which can help cancer grow or become resistant to it. IFNs affect practically all cell types, and through their cellular effects, they can be useful in preventing the genesis and growth of tumours as well as causing their regression.

Insights on the ways by which IFNs exercise their anticancer effect have defined the cellular functions of Interferon- Stimulated Gene (ISG) products and helped to comprehend host resistance to tumour emergence. These later proteins are responsible for both the antiviral and immunoregulatory functions of IFNs in addition to their anticancer properties. Currently, more than a thousand genes have been found to be controlled by IFN signalling pathways. A significant factor in the emergence of several human malignancies is the suppression of IFNs and impacts on their controlled gene products in and by malignant cells. Prostate, breast, head and neck, and pancreatic cancer risk are all increased by the germ-cell mutation of an ISG RNASEL.

Somatic homozygous deletions in the IFN locus at 9p21 and mutations of ISGs in melanoma, colorectal, lung, and hematologic cancers have been discovered using gene expression profiling and cytogenetic analysis. It is probable that both genetic and epigenetic IFN signalling silencing affect tumour formation. IFNs to play their powerful immunomodulatory functions in preventing chemical carcinogenesis and regulating the formation of syngeneic and transplanted tumours, activated Natural Killer (NK) and T cells are essential. IFNs not only serve as the main catalyst for the synthesis of IFNs- and IFN-, but they also have an impact on dendritic cell maturation. The success of IFNs and/or inducers in inhibiting tumour formation and progression is likely due to these activities of endogenous IFNs-, IFN-, and IFN-. However, these immunomodulatory effects might or might not be the same as those causing a clinical tumour regression when IFNs are given alone or in combination with other forms of therapy. Only little amounts of impure IFNs were available prior to the development of recombinant DNA technology for protein synthesis in prokaryotes. IFNs were the first recombinantly generated proteins that had not previously been widely used in clinical therapy.

The U.S. Food and Drug Administration (FDA) subsequently granted permission for a specified human protein with significant cell regulatory effects for the treatment of human cancer, marking the achievement of a long-awaited milestone. IFNs were subsequently established as the standard for biologic response modifiers in clinical oncologic treatment. This chapter discusses the structure of this family of cytokines, receptor contacts, and signal transduction pathways, mechanisms of action, the ISGs, and clinical anticancer activity with a focus on research in human cells. The cytokine family known as Interferons (IFNs) was discovered over 50 years ago due to their antiviral capabilities. IFNs have a part in antitumor and immunomodulatory responses in addition to having significant antiviral effects. Type I (IFN-subtypes, IFN-, etc.) and type II (IFN-) are the two main groups of IFNs. Recently identified additional IFNs (IFN-like cytokines; IFN- subtype) have not yet been fully characterized. IFNs of type I and type II employ different but related receptor systems. The function and signalling pathways of various cytokines and their receptors are now better understood because to research on these receptor systems. IFN-inducible proteins in receptive cells are principally responsible for the biological effects of IFNs.

The earliest recombinant DNA-produced IFNs were type I IFNs, which were utilized therapeutically to treat cancer, autoimmune disorders, and viral infections. By the generation of reactive oxidant species, IFN-plays significant roles in the regulation of illnesses brought on by intracellular bacteria, parasites, and fungus. It may also play a crucial role in the lung's adaptive immunological responses, as well as in the development of pulmonary disorders such pulmonary fibrosis and asthma.